Department of Pharmaceutics, University Institute of Pharmacy, Faculty of Technology, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India.
Recent Pat Nanotechnol. 2015;9(2):94-105. doi: 10.2174/187221050902150819151841.
Eye is a vital sense organ of our body and any disorder can lead to serious medical implications that may put great financial burden on patient and their family. Effective drug delivery to the eye is a challenging proposition for the pharmaceutical scientist. Eye drops have been globally accepted as a formulation for anterior segment applications. On one hand it is widely used owing to its convenience but is also associated with some limitations in terms of desired pharmacological and pharmacokinetic profile, dosing frequency, systemic untoward effects, patient noncompliance, low drug bioavailability due to transient contact time, rapid washout by tearing and nasolacrimal drainage. The need to overcome these major issues related to ocular pharmacotherapy has been long recognized. Several novel nanocarriers including nanolipid based carrier systems have been widely explored and investigated for ophthalmic applications. These include solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes, in situ gels, niosomes, mucoadhesive systems and discomes. Since lipids have similar structure to human cell lipids, their biodegradable, non-toxic and biocompatible profile are particularly useful. Additionally, they also offer protection against drug degradation, impart controlled drug release characteristics and site specific delivery. This review explores the potential feasibility of lipid component in formulation of nanomedicine for ophthalmic delivery and reports the clinical findings in order to improve the ocular pharmacotherapy. Here, we also discussed for patents related to the topic.
眼睛是我们身体的一个重要感觉器官，任何障碍都可能导致严重的医疗后果，给患者及其家庭带来巨大的经济负担。将药物有效递送至眼部对于制药科学家来说是一项极具挑战性的任务。滴眼剂已在全球范围内被接受为前节应用的制剂。一方面，由于其便利性而被广泛使用，但在理想的药理学和药代动力学特性、给药频率、全身不良反应、患者顺应性、由于短暂接触时间导致的低药物生物利用度、眨眼和鼻泪液引流导致的快速清除等方面也存在一些局限性。长期以来，人们一直认识到需要克服与眼部药物治疗相关的这些主要问题。已经广泛探索和研究了几种新型纳米载体，包括基于纳米脂质的载体系统，用于眼科应用。这些包括固体脂质纳米粒（SLN）、纳米结构脂质载体（NLC）、脂质体、原位凝胶、类脂体、黏膜黏附系统和圆盘。由于脂质与人类细胞脂质具有相似的结构，它们具有可生物降解、无毒和生物相容性的特点，特别有用。此外，它们还能保护药物免受降解，赋予药物控制释放特性和靶向递送。本综述探讨了脂质成分在眼科递药纳米医学制剂中的潜在可行性，并报告了临床研究结果，以改善眼部药物治疗。在这里，我们还讨论了与该主题相关的专利。
